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Abstract 
 
Background  Nogo-B (Reticulon 4B) accentuates hepatic fibrosis and cirrhosis, but the mechanism remains 
unclear.  The aim of this study was to identify Nogo-B’s role in hepatic stellate cell (HSC) apoptosis in cirrhotic 
livers. 
Methods  Cirrhosis was generated by carbon tetrachloride inhalation in wild-type (WT) and Nogo-A/B knockout 
(NGB KO) mice.  HSCs were isolated from WT and NGB KO mice and cultured for activation and 
transformation to myofibroblasts (MF-HSCs).  Human hepatic stellate cells (LX2) were used to assess apoptotic 
responses of activated HSCs after silencing or overexpressing NGB. 
Results  Livers from cirrhotic NGB KO mice demonstrated significantly reduced fibrosis (p = 0.012) compared 
with those of WT mice.  Apoptotic cells were more prominent in fibrotic areas of cirrhotic NGB KO livers.  
NGB KO MF-HSCs revealed significantly elevated levels of apoptotic markers, cleaved PARP, caspase-3 and -8 
(p < 0.05), compared with WT MF-HSCs in response to staurosporine (STS).  Treatment with tunicamycin, an 
ER stress inducer, increased cleaved caspase-3 and -8 levels in NGB KO MF-HSCs compared with WT MF-HSCs 
(p < 0.01).  In LX2 cells, NGB knockdown enhanced apoptosis in response to STS, whereas NGB 
overexpression inhibited apoptosis. 
Conclusion  The absence of Nogo-B enhances apoptosis of HSC in experimental cirrhosis.  Selective blockade 
of Nogo-B in HSCs may represent a potential therapeutic strategy to mitigate liver fibrosis. 
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Introduction 
 
 Liver fibrosis and its end-stage manifestation cirrhosis represent clinical challenges worldwide.  
Hepatic stellate cell (HSC) activation is the cardinal feature that results in hepatic fibrosis.  When stimulated by 
reactive oxygen species or cytokines in response to various hepatic insults, quiescent HSCs are transformed to 
myofibroblasts (MF-HSCs) that proliferate and secrete collagen.1-4  Studies have demonstrated that apoptosis of 
activated HSCs can reverse fibrosis.5-13  Thus, the mechanisms that control MF-HSC apoptosis may represent 
potential therapeutic targets that result in fibrosis resolution.14-16 
 Nogo-B, also known as Reticulon 4B, is a member of the reticulon protein family that are localized 
primarily to the endoplasmic reticulum (ER).17, 18  Four groups of Reticulons, 1, 2, 3 and 4, exist with each having 
multiple isoforms.  Reticulon 4 has three isoforms, Nogo-A, B and C.  The most recognized isoform, Nogo-A 
(200 kDa), a potent neural outgrowth inhibitor,19-21 is mainly expressed in the nervous system.22-24  Nogo-C (25 
kDa) is highly expressed in the differentiated muscle fibers and somewhat in the brain;17, 18, 22 its function remains 
unclear. 
 Nogo-B (55 kDa), a splice variant of Nogo-A, is expressed in most tissues and has been reported for its 
role in modulating endothelial and smooth muscle cellular responses following injury in a variety of organs/tissues, 
including blood vessels,25, 26 lung,27, 28 kidney,29 and liver.30  We previously demonstrated that the absence of 
Nogo-B in a murine model blocks the progression of fibrosis/cirrhosis and the development of portal 
hypertension.30  Further, we showed that lack of Nogo-B decreases the levels of α-smooth muscle actin (α-SMA), 
a marker of MF-HSCs, in murine cholestatic livers.  These findings led us to hypothesize that absence of Nogo-B 
may increase the susceptibility of MF-HSCs to apoptosis thereby reducing fibrosis/cirrhosis in mice.  In this 
study, we investigated the role of Nogo-B in MF-HSC apoptosis in vivo and in vitro. 
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Materials and Methods 
 
Animals 
 All animal studies were approved by the Institutional Animal Care and Use Committees of Yale 
University and Veterans Affairs Connecticut Healthcare System.  Studies were performed in adherence with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals.  Nogo-A/B knockout (NGB 
KO) mice were a gift from Stephen Strittmatter31 and Mark Tessier-Lavigne.32 
 
Induction of hepatic fibrosis and cirrhosis 
 Five male NGB KO and their littermate wild-type (WT) mice at the age of 1 month were exposed to 
carbon tetrachloride (CCl4) by inhalation for 12 weeks.33, 34  Phenobarbital (0.35 g/L) was added to the drinking 
water 3 days prior to CCl4 exposure to accentuate fibrosis/cirrhosis.  Mice were placed in a gas chamber (60 x 40 
x 20 cm) under a fume hood and exposed to CCl4 gas three times a week.  The duration of CCl4 inhalation was 
1–2 minutes for the first 3 weeks and was increased to 3–5 minutes thereafter.  CCl4 exposure was stopped 5–7 
days before the experiment.  Phenobarbital was no longer added to the drinking water at the time CCl4 exposure 
was stopped.  Age-matched untreated WT and NGB KO mice were used as treatment controls.  Liver samples 
were isolated and fixed in formalin.  Paraffin-embedded liver samples were prepared for histological analyses. 
 
Sirius red staining 
 Histological specimens were embedded in paraffin and cut to 6μm-thick sections.  Sections were 
deparaffinized by three-time washes of xylene for 5 minutes each, and rehydrated with 100%, 90% and 70% 
ethanol for 5minutes each.  After rinsing in distilled water for 5 minutes, sections were incubated in 0.1% Sirius 
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red solution (Sigma-Aldrich, St. Louis, MO) for 90 minutes, soaked in 0.5% acetic acid buffer, and dehydrated 
gradually with 70%, 90% and 100% ethanol and 3 times with xylene for 5 minutes.  Fibrosis was determined by 
calculating the percent Sirius red–positive area (i.e., collagen-positive area) over the total area analyzed.  Image J1.43u 
(Wayne Rasband, National Institutes of Health, Bethesda, MD) was used for image analysis of the entire liver sections.  
At least 20 images per liver section were randomly taken and used for the analyses.30 
 
Immunohistochemistry 
 Paraffin-embedded sections (6μm-thick) were deparaffinized and rehydrated as described above.  
Antigen retrieval was performed by placing sections in 10mM sodium citrate buffer pH 6.0, heated in a microwave, 
placed in a steamer for 30 minutes, and steadily cooled down on the bench top for 20 minutes.  Sections were 
then treated with 3% hydrogen peroxidase diluted with methanol, followed by blocking with 5% Donkey serum 
plus 1% bovine serum albumin (BSA) in PBS.  After blocking non-specific biotin and avidin using a kit 
(Avidin/Biotin blocking kit, Vector Laboratories, Burlingame, CA), sections were incubated overnight at 4oC with 
cleaved caspase-3 antibody (rabbit, 1:100, Cell Signaling, Danvers, MA).  After washing three times with 
Tris-buffered saline with 0.05% Tween20 (TBST) for 5 minutes, sections were incubated with biotinylated 
anti-rabbit IgG (1:500, Jackson ImmunoResearch Laboratories, West Grove, PA) and avidin conjugated horse 
radish peroxidase (Vector Laboratories) for 30 minutes each at room temperature.  After washing three times with 
TBST, sections were incubated with DAB substrate (Vector Laboratories) for color development, followed by 
counterstaining with hematoxylin.  Sections were then dehydrated and mounted.  Images were taken using a 
light microscope (Eclipse 80i, Nikon, Melville, NY) and analyzed by Image J1.43u. 
 
Dual staining of TdT-mediated dUTP nick-end labeling (TUNEL) and α-SMA 
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 O.C.T.-embedded frozen liver tissues were cut to 6μm-thick sections and fixed with 4% 
paraformaldehyde (PFA) in PBS for 20 minutes at room temperature, followed by washing with PBS three times 
for 5 minutes each.  Antigen retrieval was performed by placing sections in 10mM sodium citrate buffer pH 6.0, 
heated in a microwave, placed in a steamer for 30 minutes, and steadily cooled down on the bench top for 20 
minutes.  Sections were then incubated with a blocking buffer including 5% Donkey serum plus 1% BSA in 
PBS-0.3% Triton-X for 1 hour, followed by the treatment with mouse Ig blocking reagent (Vector Laboratories) 
for 1 hour at room temperature.  Sections were then incubated with a mouse monoclonal anti-αSMA (1:1,000; 
Sigma-Aldrich) at room temperature for 1 hour.  After washing three times with TBST for 5 minutes each, 
sections were incubated with Alexa Fluor 555 donkey anti-mouse IgG (1:500; Invitrogen, Grand Island, NY) for 
30 minutes at room temperature.  After these processes, TUNEL staining was performed using a commercial kit 
(In Situ Cell Death Detection Kit; Roche Diagnostics, Indianapolis, IN) for 1 hour at room temperature.  After 
washing three times with TBST for 5 minutes each, sections were mounted with a DAPI containing media 
(Invitrogen).  Images were taken by a fluorescent microscope (Eclipse E800; Nikon) and recorded using 
Openlab3 software (PerkinElmer, Waltham, MA). 
 
Isolation of hepatic stellate cells (HSCs) 
 Primary HSCs were isolated from WT and NGB KO mice by in situ perfusion of livers with 
pronase-collagenase, followed by density gradient centrifugation using Nycodenz (Histodenz; Sigma-Aldrich) 
density gradients as described.35, 36  HSCs were cultured in Dulbecco’s Modified Eagle’s Medium with high 
glucose (DMEM; GIBCO, Invitrogen) supplemented with 10% fetal bovine serum (FBS), antibiotics (100 U/mL 
penicillin and 100 μg/mL streptomycin) and 1% L-glutamine in humidified air containing 5% CO2 at 37oC.  
HSCs were cultured for more than 14 days to fully transform to myofibroblasts (MF-HSCs).37 
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Treatment of MF-HSCs with staurosporine, FAS ligand and tunicamycin 
 MF-HSCs were seeded in 6-well tissue culture plates at a density of 2.0 x 105 cells/well and incubated in 
humidified air containing 5% CO2 at 37oC overnight.  Media was changed to serum free conditions in DMEM for 
24 hours, and MF-HSCs were treated with 1μM staurosporine (STS; Calbiochem, Germany) for 0, 2, 4, 6, 8 and 
10 hours to induce apoptosis.  To determine whether apoptosis was Fas receptor dependent, MF-HSCs were 
treated with 50 ng/mL Fas ligand (FasL; Calbiochem) in the presence of 20 ng/mL cycloheximide (CHX; 
Calbiochem) for 10 hours.  To induce ER stress, MF-HSCs were treated with tunicamycin at concentrations of 0, 
0.5, 1, 2, 5 and 10 μM for 24 hours. 
 
Hepatocyte isolation 
 Hepatocytes were isolated from WT and Nogo-B KO mice by collagenase perfusion as previously 
described38 with slight modifications.  Briefly, cells were cultured on collagen-coated cell culture dishes or glass 
coverslips in Hepatocyte Maintenance Medium (HMM; Clonetics/Lonza, Basel, Switzerland) supplemented with 
HMM SingleQuots (Clonetics/Lonza) and Matrigel (BD Biosciences, San Jose, CA).  An initial coating density 
was 0.4x106/ml.  On the following day, cells were replaced with medium without any supplementation and 
incubated for 24 hours.  Cells were then subjected to experiments for STS treatment. 
 
Western blot analysis 
 After drug treatment, cells were collected in a lysis buffer containing 50mM Tris HCl, 0.1mM EGTA, 
0.1mM EDTA, 0.1% SDS, 0.1% deoxycholic acid, 1% (vol/vol) Nonidet P-40, 5mM sodium fluoride, 1mM 
sodium pyrophosphate, 1mM activated sodium vanadate, 0.32% protease inhibitor cocktail (Roche Diagnostics), 
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and 0.027% Pefabloc (Roche Diagnostics).  Lysates were centrifuged at 14,000 rpm, 4oC for 10 minutes.  
Protein concentration was determined using a Lowry assay.  An equal amount of protein (10-20 μg) from each 
sample was loaded onto sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and 
transferred to 0.2 μm nitrocellulose membranes (BIO-RAD, Hercules, CA).  After blocking with 5% nonfat dry 
milk in 0.1% TBST, membranes were probed with rabbit anti-Nogo serum (1761A, 1:10,000, a kind gift from Dr. 
William C. Sessa, Yale University), goat anti-Nogo (N-18, 1:200; Santa Cruz Biotechnology Inc., Santa Cruz, CA), 
mouse anti-Hsp90 (1:1000; BD Biosciences), mouse anti-Bip (1:1000; BD Biosciences), rabbit anti-PARP 
(1:1,000; Cell Signaling), rabbit anti-cleaved caspase-3 (1:1,000; Cell Signaling), rabbit anti-cleaved caspase-8 
(1:1,000; Cell Signaling), rabbit anti-Bcl-xL (1:1,000; Cell Signaling), mouse anti-caspase-9 (1:1,000; Cell 
Signaling), or mouse anti-β actin (1:5,000; Sigma-Aldrich).  After washing three times with TBST for 10 minutes, 
membranes were incubated with fluorophore-conjugated secondary antibodies (either 680nm or 800nm emission).  
Detection and quantification of bands were performed using the Odyssey Infrared Imaging System (Li-Cor 
Biotechnology, Lincoln, NE).  Hsp90 and β-actin were used for loading controls. 
 
TUNEL and Annexin V staining 
 MF-HSCs were fixed with 4% paraformaldehyde (PFA) in PBS for 1 hour at room temperature, 
followed by washing with PBS three times for 5 minutes each.  MF-HSCs were then incubated with a 
permeabilization buffer containing 0.1% Triton X-100 in 0.1% sodium citrate on ice for 5 minutes.  TUNEL 
staining was performed using a commercial kit (In Situ Cell Death Detection Kit; Roche Diagnostics) by 
incubating MF-HSCs for 1 hour at room temperature.  Recombinant DNase I (Roche Diagnostics) 3 U/mL was 
incubated for 10 minutes as a positive control prior to labeling procedures.  The label solution conjugated with 
fluorescein alone was used as a negative control.  After washing three times with PBS for 5 minutes each, 
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MF-HSCs were mounted with a mounting media containing DAPI (Invitrogen).  Annexin V staining was 
performed using Alexa Fluor 488-conjugated Annexin V/Dead Cell Apoptosis Kit (Molecular Probes; Invitrogen).  
Images were taken using a fluorescent microscope (Eclipse E800; Nikon) and recorded with Openlab3 software 
(PerkinElmer). 
 
Nogo-B knockdown in human hepatic stellate cell line (LX2) 
 LX-2 cells were a kind gift from Dr. Scott L. Friedman (Mount Sinai School of Medicine, NY).39  Cells 
were seeded in 6-well tissue culture plates at a density of 1.5 x 105 cells/well and incubated in humidified air 
containing 5% CO2 at 37oC for overnight.  Cells were transfected with 100nM Nogo-B siRNA in 750 μL 
OptiMEM (GIBCO, Invitrogen) with 2 μl Oligofectamine (Invitrogen) and incubated for 6 hours.  Then, 750 μL 
of DMEM containing 20% FBS and 2% L-glutamine was added to each well.  After 48 hours of incubation, these 
cells were starved in DMEM without FBS for 24 hours and treated with 100nM STS for0, 2, 4, 6, 8, and 10 hours. 
 
Nogo-B overexpression in LX2 
 LX2 cells were seeded in 12-well tissue culture plates at a density of 1.0 x 105 cells/well and incubated 
in humidified air containing 5% CO2 at 37oC for overnight.  Cells were transfected with 0.5 μg of HA-tagged 
Nogo-B plasmid (or pcDNA3 vector alone as a negative control) in 500 μL OptiMEM (GIBCO, Invitrogen) with 
1.5 μl FuGENE 6 (Roche Diagnostics) and incubated for 6 hours.  Then, 500 μL of DMEM containing 10% FBS 
and 1% L-glutamine was added to each well.  After 48 hours of incubation, cells were starved in DMEM without 
FBS for 24 hours, followed by the treatment with 100nM STS for 4 and 8 hours. 
 For immunocytochemistry, cells were washed with cold PBS and fixed with 4% PFA in PBS for 20 
minutes at room temperature.  After washing three times with PBS for 5 minutes each, cells were incubated in a 
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buffer containing 0.3% Triton X-100, 5% donkey serum and 1% BSA in PBS at room temperature for 1 hour.  
After washing with PBS, cells were incubated with antibodies including rat anti-HA (1:1,000; Roche Diagnostics) 
and rabbit anti-cleaved caspase-3 (1:1,000; Cell Signaling), which were diluted with 1% BSA in PBS at 4oC for 
overnight.  Cells were then incubated with Alexa Fluor 488 donkey anti-rat IgG (1:500; Invitrogen) or Alexa 
Fluor 588 donkey anti-Rabbit IgG (1:500; Invitrogen) as a secondary antibody for 1 hour at room temperature.  
Cells were mounted with a DAPI containing media (Invitrogen).  Images were taken by a fluorescent microscope 
(Eclipse E800; Nikon) and recorded using Openlab3 software (PerkinElmer). 
 
Statistical analysis 
 Data were expressed as mean + standard error (SE).  Statistical differences among the mean values of 
multiple groups were determined using analysis of variance (ANOVA) followed by a Student t test.  Values of p 
< 0.05 were considered statistically significant. 
 11
Results 
 
Lack of Nogo-B reduces fibrosis and facilitates apoptosis in fibrotic areas of the mouse cirrhotic liver. 
 Sirius red staining was performed in cirrhotic livers isolated from WT and NGB KO mice that 
underwent CCl4 inhalation for 12 weeks (Figure 1A left panel).  Liver fibrosis was significantly reduced in NGB 
KO livers compared with WT livers (Figure 1A left and right panels, p = 0.012).  This is similar to the results 
observed using a murine model of bile duct ligation (BDL).30  Apoptotic cells, as indicated by cleaved caspase-3 
immunolabeling, were seen in fibrotic regions of Nogo-B KO livers, whereas they were much less apparent in WT 
livers (Figure 1B).  NGB KO cirrhotic livers demonstrated co-localization of TUNEL staining with α-SMA 
positive cells, while TUNEL staining was not apparent in WT cirrhotic livers (Figure 1C).  These results suggest 
that the lack of Nogo-B reduces fibrosis and enhances apoptosis of activated HSCs in experimental cirrhosis. 
 
Lack of Nogo-B facilitates apoptosis of myofibroblasts derived from hepatic stellate cells (MF-HSCs). 
 Nogo-B’s role in apoptosis of MF-HSCs was examined using staurosporine (STS), an inducer of 
apoptosis.40-42  WT and NGB KO MF-HSCs were treated with 1μM STS for 16 hours and examined for TUNEL 
and Annexin V labeling.  NGB KO MF-HSCs showed significantly higher percentages of TUNEL and Annexin 
V positive nuclei compared with WT MF-HSCs (Figures 2A and B, p < 0.01). 
 We also determined the levels of several apoptotic markers in WT and NGB KO MF-HSCs after 
treatment with 1μM STS for 0, 2, 4, 6, 8 and 10 hours (Figure 3).  Levels of cleaved PARP were increased in a 
time-dependent manner in both WT and NGB KO MF-HSCs, but were significantly higher in NGB KO MF-HSCs 
4, 6 and 10 hours after STS treatment (p < 0.05 for 4 and 6 hours and p < 0.01 for 10 hours, Figure 3B top panel).  
Similarly, cleaved caspase-3 levels were significantly increased in NGB KO MF-HSCs 4, 6 and 8 hours after STS 
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treatment (p < 0.05 for 4 and 6 hours and p < 0.01 for 8 hours, Figure 3B middle panel).  The levels of cleaved 
caspase-8 were also significantly increased in NGB KO MF-HSC 4, 6 and 8 hours after STS treatment (p < 0.05, 
Figure 3B bottom left panel).  Cleaved caspase-9 and Bcl-xL levels did not differ between these two groups at all 
time points examined (Figure 3B bottom middle and right panels).  This may reflect the fact that Bcl-xL 
primarily acts on mitochondria and prevents apoptosis by inhibiting the activity of caspase-9.43, 44  These results 
indicate that the lack of Nogo-B facilitates apoptosis of MF-HSCs in response to STS. 
 
Lack of Nogo-B does not influence hepatocyte apoptosis in response to staurosporine (STS). 
 To investigate the possibility that Nogo-B may modulate apoptosis in hepatocytes, hepatocytes from WT 
and NGB KO mice were treated with STS (Figure 4).  Hepatocytes required a higher dose of STS than MF-HSCs 
to induce apoptosis (10 vs. 1 μM, respectively).  Moreover, there was no difference in the levels of apoptotic 
markers between WT and NGB KO hepatocytes.  These results indicate that the absence of NGB preferentially 
sensitize MF-HSCs rather than hepatocytes to apoptosis under conditions of experimental cirrhosis. 
 
Knockdown of Nogo-B increases apoptosis in human hepatic stellate cells (LX2). 
 To confirm Nogo-B’s role in apoptosis in human MF-HSCs, LX2 cells were transfected with Nogo-B 
siRNA to suppress Nogo-B expression.  We then tested apoptosis in those cells, treated with100nM STS for 0, 2, 
4, 6, 8 and 10 hours (Figure 5).  Nogo-B siRNA resulted in 66% reduction of Nogo-B expression.  Similar to the 
results in mouse MF-HSCs, the levels of cleaved PARP and caspase-3 were increased in LX2 cells treated with 
NGB siRNA compared with controls, while the levels of cleaved caspase-9 and Bcl-xL did not differ.  Consistent 
with mouse MF-HSCs, knockdown of Nogo-B resulted in enhanced apoptosis in human MF-HSCs in response to 
STS. 
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Overexpression of Nogo-B blocks apoptosis in human hepatic stellate cells (LX2). 
 To determine the effect of Nogo-B overexpression on apoptosis of human MF-HSCs, LX2 cells were 
transfected with HA-tagged human Nogo-B plasmid and treated with 100nM STS for 8 hours.  The transfection 
resulted in a 7-fold higher level of Nogo-B over the endogenous Nogo-B level found in non-transfected LX-2 cells 
(data not shown).  As shown in Figure 6, the majority of HA-Nogo-B positive cells (green staining) were 
negative for cleaved caspase-3 (red staining).  In fact, the percentage of cleaved caspase-3 positive cells was 
significantly lower in HA-Nogo-B positive cells than in non-transfected cells (4.2 vs. 29.4%, respectively, p < 
0.01).  These results suggest that MF-HSCs become resistant to apoptosis with Nogo-B overexpression.  This 
data also lends support to our earlier data that the lack of Nogo-B facilitates apoptosis of MF-HSCs. 
 
Nogo-B is involved in ER stress-induced apoptosis in myofibroblasts derived from hepatic stellate cells 
(MF-HSCs). 
 In order to examine how Nogo-B influences apoptosis of MF-HSCs, WT and NGB KO MF-HSCs were 
treated with tunicamycin, an ER stress inducer, and Fas ligand (FasL), an inducer of apoptosis through the death 
receptor pathway.  Tunicamycin treatment (0, 0.5, 1, 2, 5 and 10 μg/mL for 24 hours) generated significantly 
higher levels (p < 0.01) of cleaved caspase-3 and -8 in NGB KO MF-HSCs than in WT MF-HSCs virtually at all 
concentrations examined, while the levels of Bip, a marker of the ER stress response, were similar in WT and 
NGB KO MF-HSCs (Figure 7A upper panels).  In contrast, FasL treatment (50 ng/mL for 10 hours in the 
presence of 20 ng/mL cycloheximide) did not affect the levels of apoptotic markers (cleaved PARP, cleaved 
caspase-3 and -8) between WT and NGB KO MF-HSCs (Figure 7B).  In addition, levels of Bcl-xL, which is 
related to the mitochondrial pathway of apoptosis, was not different between WT and NGB KO MF-HSCs in 
 14
response to STS (Figure 3B bottom left panel).  These results suggest that the higher degree of apoptosis 
observed in NGB KO MF-HSCs is attributable in part to ER stress-induced apoptosis (Figure 7C). 
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Discussion 
 
 Experimental studies have demonstrated that inducing HSC apoptosis may reverse hepatic fibrosis.45-49  
In this study, we have discovered that lack of Nogo-B reduces liver fibrosis and enhances apoptosis of 
myofibroblasts derived from HSCs (MF-HSCs, i.e., activated HSCs) in mice that underwent carbon tetrachloride 
(CCl4) inhalation for 12 weeks.  Enhanced apoptosis due to the absence of Nogo-B was recapitulated in vitro as 
well.  Cultured myofibroblasts derived from HSCs of Nogo-B KO mice as well as human hepatic stellate cells 
(LX2) with Nogo-B gene knockdown demonstrated a greater degree of apoptosis than their respective controls in 
response to an apoptotic stimulus.  Furthermore, Nogo-B overexpression decreased susceptibility of LX2 cells to 
apoptosis.  These findings suggest that Nogo-B has an anti-apoptotic effect on MF-HSCs and that the enhanced 
apoptosis of MF-HSCs lacking Nogo-B may be responsible for the reduced fibrosis observed in the livers of 
Nogo-B KO mice. 
 We previously reported that Nogo-B levels are elevated in fibrotic areas of human cirrhotic liver 
specimens as well as in mouse cholestatic models of fibrosis after bile duct ligation.  Nogo-B gene deletion 
blocks the progression of liver cirrhosis and portal hypertension, suggesting that Nogo-B promotes liver fibrosis.  
This anti-fibrotic effect was mediated through TGFβ/Smad2 signaling in myofibroblasts.30  The current study 
adds to these earlier findings by showing that Nogo-B represents an anti-apoptotic factor for HSCs in the setting of 
experimental cirrhosis.  Moreover, this study confirms that Nogo-B facilitates fibrosis in the CCl4 model of 
cirrhosis and supports our earlier studies that demonstrate a pro-fibrotic role for Nogo-B in the liver.  Previous 
work using Nogo-B KO mice in a kidney injury model observed no significant differences in tissue fibrosis.29  
The length of injury and the different organ systems studied may account for these different outcomes. 
 We have also examined pathways through which Nogo-B carries out anti-apoptosis of MF-HSCs with a 
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focus on ER stress, Fas ligand, and mitochondrial pathways. Since ER stress induces apoptosis in HSCs12 and 
Nogo-B regulates ER structure,17, 18, 28, 50 we hypothesized that Nogo-B’s anti-apoptotic effect on MF-HSCs might 
be mediated by ER stress.  In fact, treatment with tunicamycin significantly increased the levels of cleaved 
caspase-3 and -8 in Nogo-B KO MF-HSCs, compared with their WT counterparts.  These indicate that Nogo-B’s 
anti-apoptotic role in MF-HSCs is due, at least in part, to its involvement in ER stress (Figure 7C).  Thus, 
Nogo-B appears to increase the susceptibility of MF-HSCs to ER stress thereby predisposing to apoptosis. 
 In contrast, our study indicates that Nogo-B’s anti-apoptotic role in MF-HSCs is not likely via the 
mitochondrial pathway, since the level of Bcl-xL, an indicator of mitochondria-mediated apoptosis, did not differ 
between WT and Nogo-B KO MF-HSCs in response to staurosporine.  Although we found significantly higher 
levels of cleaved caspase-8 in Nogo-B KO MF-HSCs in response to staurosporine, caspase-8 is known to be 
activated through the ER stress pathway51 and/or the death receptor pathway.52-54  In addition, treatment with 
FasL, a pro-apoptotic death ligand, did not generate any difference in the level of cleaved caspase-8 between these 
two groups of MF-HSCs ruling out a role for Fas mediated cell death. 
 Nogo-B’s involvement in apoptosis has also been reported in cancer cells.  However, those reports are 
conflicting.  One study shows increased apoptosis in HeLa derived D98/AH2 cells transiently transfected with 
Nogo-B.55  Another study also presents Nogo-B’s pro-apoptotic effect on CGL4 (a HeLa-derived cell line), 
SaOS-2 (an osteosarcoma cell line), MeWo (a melanoma cell line), HT-1080 (a fibrosarcoma cell line) and HFL 
(the immortalized, non-malignant, human fibroblast cell line), having them transiently transfected with Nogo-B.56  
In contrast, Oertle et al. document that SaOS-2 stably transfected with Nogo-B does not differ in the apoptotic 
effect from its control.57  These discrepancies may suggest that timing and length of Nogo-B overexpression are a 
key to induce apoptosis in certain cancer cells and that those cancer cells with stable overexpression of Nogo-B 
might develop an adaptive machinery that protects them from apoptosis.  Further studies are needed to clarify 
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these contradictions.  An anti-apoptotic role of Nogo-B has also been observed in lung cells in pulmonary 
hypertension.28  Overall, Nogo-B may function as a pro-apoptotic or anti-apoptotic protein, depending on the 
specific cell type. 
 Apoptosis can also mediate pro-fibrotic responses in the liver depending on the cell type involved.  
Hepatocyte apoptosis is thought to facilitate fibrosis by triggering and maintaining HSC activation in response to 
hepatic insults.58  To address this issue, we examined whether the levels of apoptotic markers (cleaved PARP, 
cleaved caspase-3 and-8, and Bcl-xL) in cultured WT and Nogo-B KO hepatocytes differed in response to 
staurosporine.  No differences in apoptotic activity were observed, indicating that Nogo-B’s anti-apoptotic effect 
is specific to MF-HSCs. 
 In conclusion, absence of Nogo-B specifically increases apoptotic responses of MF-HSCs, which is 
associated with a reduction in hepatic fibrosis.  Therefore, Nogo-B may be a potential target for the treatment of 
liver fibrosis/cirrhosis. 
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Figure Legends 
 
Figure 1 
Lack of Nogo-B decreases liver fibrosis and increases apoptotic cells in fibrotic areas in mice. 
A. Representative images of Sirius red staining (left panel, Scale bar; 100μm) and percentages of Sirius red 
positive areas in cirrhotic livers from wild-type (WT) and NGB KO mice.  Values represent mean + standard 
error (SE) (* p < 0.05).  B. Immunohistochemistry of cleaved caspase-3 in cirrhotic livers isolated from WT and 
NGB KO mice (Scale bar; 100μm).  Red arrowheads in the enlarged images (lower panel) indicate cleaved 
caspase-3 positive cells in the fibrotic area.  Serial liver sections from the same mice were stained for Sirius red 
and cleaved caspase-3.  At least 5 images were taken for each group.  C. Co-localization of apoptotic cells with 
alpha-smooth muscle actin (α-SMA) in cirrhotic livers isolated from WT and NGB KO mice that underwent bile 
duct ligation (Scale bar; 50μm).  α-SMA is shown in red, apoptotic (TUNEL positive) cells in green, and nuclei 
stained with DAPI in blue.  Arrowheads indicate apoptotic cells.  At least 5 images were taken for each group. 
 
Figure 2 
Lack of Nogo-B facilitates apoptosis of mouse myofibroblasts derived from hepatic stellate cells (MF-HSCs) 
in vitro. 
MF-HSCs were treated with 1μM staurosporine (STS) for 16 hours to induce apoptosis.  A. TUNEL staining 
(green: TUNEL positive nuclei, blue: DAPI, Scale bar; 100μm) and percentages of TUNEL positive nuclei in WT 
and NGB KO MF-HSCs.  B. Annexin V staining (green: Annexin V positive nuclei, blue: DAPI, Scale bar; 
100μm) and percentages of Annexin V positive nuclei in WT and NGB KO MF-HSCs.  The numbers of TUNEL 
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and Annexin V positive nuclei (green) were divided by the total numbers of nuclei determined by DAPI staining 
(blue).  At least 5 images were taken for each group.  Values represent mean + SE (** p < 0.01). 
 
Figure 3 
Markers of apoptosis are increased in mouse myofibroblasts derived from hepatic stellate cells (MF-HSCs) 
that lack Nogo-B. 
MF-HSCs were treated with 1μM staurosporine (STS) for 0, 2, 4, 6, 8 and 10 hours.  A. A representative western 
blot analysis of apoptotic markers, including cleaved PARP, cleaved caspase-3, -8 and -9, and Bcl-xL.  β-actin 
was used as a loading control.  B. Quantification of western blot analysis from at least three to five independent 
experiments.  Values represent mean + SE (*p < 0.05 and **p < 0.01). 
 
Figure 4 
Lack of Nogo-B does not influence hepatocyte apoptosis in response to staurosporine (STS). 
Hepatocytes were isolated from wild-type (WT) and NGB KO mice and treated with 10μM STS for 0, 2, 4, 6, 8 
and 10 hours.  Heat shock protein 90 (Hsp90) was used as a loading control. 
 
Figure 5 
Knockdown of Nogo-B increases apoptosis in human hepatic stellate cells (LX2). 
LX2 cells with or without Nogo-B siRNA were treated with 100nM staurosporine (STS) for 0, 2, 4, 6, 8 and 10 
hours.  Western blot analysis for apoptotic markers, including cleaved PARP, cleaved caspase-3 and -9, and 
Bcl-xL, was performed.  β-actin was used as a loading control. 
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Figure 6 
Overexpression of Nogo-B blocks apoptosis in human hepatic stellate cells (LX2). 
LX2 cells were transfected with HA-tagged human Nogo-B plasmid to overexpress Nogo-B.  Cells were treated 
with 100nM staurosporine (STS) for 8 hours.  Representative immunofluorescence images of HA and cleaved 
caspase-3 in LX2 cells 8 hours after STS treatment (green: HA, red: cleaved caspase-3, blue: DAPI).  Arrows 
indicate HA-Nogo-B positive cells.  Scale bar; 20μm.  Cleaved caspase-3 positive cells were counted in LX-2 
cells with and without Nogo-B overexpression and divided by the total numbers of nuclei, respectively.  At least 
8 images were taken per group.  Values represent mean + SE (** p < 0.01). 
 
Figure 7 
Lack of Nogo-B increases ER stress-induced apoptosis in mouse myofibroblasts derived from hepatic 
stellate cells (MF-HSCs). 
A. MF-HSCs were treated with tunicamycin (0, 0.5, 1, 2, 5 and 10 μg/mL) for 24 hours.  A representative western 
blot analysis (left panel) from at least three to five independent experiments and quantification of cleaved 
caspase-3 and -8 levels (right panels).  Bip was used as an ER stress marker and β-actin was used as a loading 
control.  Values represent mean + SE (**p < 0.01).  B. MF-HSCs were treated with 50 ng/mL Fas ligand (FasL) 
for 10 hours in the presence of 20 ng/mL cycloheximide (CHX), and blotted for cleaved PARP, cleaved caspase-3 
and -8, and Nogo-B.  β-actin was used as a loading control.  C. A diagram of apoptotic pathways that includes a 
putative role of Nogo-B.  At least three major apoptotic pathways exist, including the death receptor-, 
mitochondria- and ER stress-mediated pathways.  Nogo-B reduces MF-HSC apoptosis by protecting cells from 
ER stress.  Bcl-xL: anti-apoptotic molecule. 
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